GenMont (3164) reported revenue of NT$35.4 million for Oct 2026, -4.1% year on year and -22.3% from the previous month. Revenue for Jan–Oct 2026 was NT$331.3 million (-1.8% year on year).
In Oct 2026, it ranked No. 113 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$35.4 million | -4.1% | -22.3% |
| Sep 2026 | NT$45.6 million | +46.9% | +50.4% |
| Aug 2026 | NT$30.3 million | +15.5% | +10.0% |
| Jul 2026 | NT$27.6 million | -12.9% | -27.0% |
| Jun 2026 | NT$37.7 million | -13.2% | +35.7% |
| May 2026 | NT$27.8 million | -3.3% | -26.4% |
| Apr 2026 | NT$37.8 million | -5.4% | -1.3% |
| Mar 2026 | NT$38.3 million | -12.6% | +133.2% |
| Feb 2026 | NT$16.4 million | -35.5% | -52.4% |
| Jan 2026 | NT$34.5 million | +14.1% | +10.0% |
| Dec 2025 | NT$31.3 million | -14.1% | -11.0% |
| Nov 2025 | NT$35.2 million | +13.7% | -4.5% |
| Oct 2025 | NT$36.9 million | +56.9% | +18.9% |
| Sep 2025 | NT$31 million | +23.5% | +18.3% |
| Aug 2025 | NT$26.2 million | -10.7% | -17.1% |
| Jul 2025 | NT$31.6 million | +7.9% | -27.2% |
| Jun 2025 | NT$43.5 million | +59.1% | +51.2% |
| May 2025 | NT$28.7 million | -12.3% | -28.0% |
| Apr 2025 | NT$39.9 million | +6.3% | -8.7% |
| Mar 2025 | NT$43.8 million | +4.6% | +72.1% |
| Feb 2025 | NT$25.4 million | -29.9% | -15.9% |
| Jan 2025 | NT$30.2 million | -13.0% | -17.1% |
| Dec 2024 | NT$36.5 million | +62.8% | +17.7% |
| Nov 2024 | NT$31 million | +32.8% | +31.7% |
| Oct 2024 | NT$23.5 million | -17.2% | -6.4% |
Jan–Oct 2026 cumulative: NT$331.3 million (-1.8% YoY)
Other Biotech & Medical companies
Compare with peers: GenMont vs PEC / GenMont vs Lotus Pharm / GenMont vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16